Loading
Latigo Biotherapeutics
Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain.
Funding
Every round, secondary, debt facility or acquisition involving Latigo Biotherapeutics that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log in